Phaseline

Companies › TORL Biotherapeutics

TORL Biotherapeutics: clinical trials, targets and expected readouts

5 active drug programs in 7 registered trials: 6 Phase 1, 1 Phase 2; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TORL-1-23
antibody drug conjugate (ADC)
–Phase 2Epithelial Ovarian Cancer; Advanced Solid Tumor; FIGO Stage III and IV Ovarian CancerNov 2026
TORL-2-307-ADC
antibody-drug conjugate
–Phase 1Advanced Solid TumorFeb 2027
TORL-4-500
antibody-drug conjugate
–Phase 1Advanced Solid TumorMar 2027
TORL-5-700–Phase 1Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin LymphomaMar 2029
TORL-3-600
antibody-drug conjugate
–Phase 1Advanced Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05948826TORL-3-600Phase 1Advanced Solid TumorOncologyJun 2026
NCT05103683TORL-1-23Phase 1Advanced Solid TumorOncologyNov 2026
NCT05156866TORL-2-307-ADCPhase 1Advanced Solid TumorOncologyFeb 2027
NCT06005740TORL-4-500Phase 1Advanced Solid TumorOncologyMar 2027
NCT06690775TORL-1-23Phase 2Epithelial Ovarian CancerOncologyOct 2027
NCT07322094TORL-1-23Phase 1FIGO Stage III and IV Ovarian CancerOncologyDec 2027
NCT07439653TORL-5-700Phase 1Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin LymphomaOncologyMar 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Avistone Biotechnology Nanjing Sanhome Pharmaceutical Shandong Boan Biotechnology Taiho Pharmaceutical Jacobio Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.